PubMed ID:
21750277
Public Release Type:
Journal
Publication Year: 2011
Affiliation: University of South Florida, Pediatrics Epidemiology Center, Tampa, FL, USA. kendra.vehik@epi.usf.edu
DOI:
https://doi.org/10.2337/dc11-0560
Authors:
Haller MJ,
Beam CA,
Krischer JP,
Mahon JL,
Schatz DA,
Skyler JS,
Sosenko JM,
TrialNet Natural History Study Group,
Vehik K
Studies:
Diabetes Prevention Trial of Type 1 Diabetes
Understanding the relationship between age and islet autoantibody (Ab) seroconversion can establish the optimal screening interval(s) to assess risk for type 1 diabetes, identify subjects who can participate in prevention trials, and determine associated costs. This study assessed the rates of seroconversion to glutamic acid decarboxylase positive (GAD65(+)), insulin positive (mIAA(+)), and insulinoma-associated protein 2 positive (ICA512(+)) in a large cohort of relatives of type 1 diabetes probands undergoing Ab rescreening in the TrialNet Natural History Study.